Myopia Management


  • Ready to take on myopia

Family products

Myopia is a chronic, progressive disease growing in both prevalence and severity,1 and there is global recognition that we should act now to treat myopia, not simply correct it. 

CooperVision® is a world leader in myopia control* and management for age-appropriate children.


MiSight® 1 day

  • First and only FDA approved* product proven to slow the progression of myopia in children, aged 8-12 at the initiation of treatment§2
  • Easy to fit, single use lens
  • Corrects refractive error and slows the elongation of the eye through ActivControlTM Technology

MiSight® Spectacle Lenses

  • Diffusion Optics Technology reduces contrast to help slow axial elongation in myopia3
  • Demonstrated safe and effective for children as young as 6 in a multi-center clinical trial≠4


U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to 4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal. Canadian Indications for Use: MiSight (omafilcon A) Soft Contact Lenses for Myopia Control may reduce the rate of myopia progression in children (6-18) and correct ametropia. Reduction of myopia progression was observed in children with wearing time of 12 hours (8-16 hours) per day, 6.4 days (5-7) per week in a clinical study. Permanent myopia control after lens treatment is discontinued is not supported by clinical studies. MiSight (omafilcon A) Soft Contact Lenses for Myopia Control are indicated for single use daily disposable wear. When prescribed for daily disposable wear, the lens is to be discarded after each removal.

Only FDA approved soft contact lens designed for myopia control.

§ Compared to a single vision 1 day lens over a 3-year period.

MiSight® Spectacle Lenses are indicated in Canada for the correction of refractive ametropia (myopia and/or astigmatism) and for the reduction in the rate of myopic progression in phakic children who are aged 6 to 13 years old with non-diseased eyes. Please refer to Instructions for Use (IFU) for information on product description, materials, parameters, indications, contraindications, warnings, and potential complications.


  1. Holden BA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016; 123(5): 1036–1042.
  2. Chamberlain P et al. A 3-year Randomized Clinical Trial of MiSightR Lenses for Myopia Control. Optom Vis Sci. 2019;96(8):556-567.
  3. Rappon J, et al. CYPRESS 12-month Results: Safety and Efficacy from a Pivotal Study of Novel Spectacle Lenses Designed to Reduce Myopia Progression. Optometry and Vision Science. 2020;97:E-abstract 200036
  4. SGV data on file 2021. Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study, 24-month results (n = 256, 14 North American sites).